Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
159 hedge funds and large institutions have $1.27B invested in Juno Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 60 increasing their positions, 43 reducing their positions, and 34 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less funds holding
Funds holding: 169 → 159 (-10)
24% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 34
31% less call options, than puts
Call options by funds: $18.7M | Put options by funds: $27M
36% less capital invested
Capital invested by funds: $1.97B → $1.27B (-$701M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$43.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.7M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$11.4M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$8.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$31M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$24.6M |
| 3 |
DFO
Duquesne Family Office
New York
|
-$14.8M |
| 4 |
BAMCO Inc
New York
|
-$13.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.44M |
JUNO Hedge Fund Activity: Q4 2016 in Review
159 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q4 2016, worth a combined $1.27B — down 36% from $1.97B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of JUNO and 26 opened new positions — a net loss of 8 holders — while 43 trimmed existing stakes and 60 added.
The largest buyer was Scopia Capital Management, opening a new position worth an estimated $43.5M. The largest seller was Fidelity Investments, cutting an estimated $31M.
- 159 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q4 2016, down from 169 in Q3 2016.
- Funds reported $1.27B of Juno Therapeutics, Inc. stock for Q4 2016, down 36% quarter-over-quarter.
- 26 funds opened new Juno Therapeutics, Inc. positions in Q4 2016 and 34 closed out, a net change of -8 holders.
- The largest Juno Therapeutics, Inc. buyer in Q4 2016 was Scopia Capital Management, an estimated $43.5M added.
- The largest Juno Therapeutics, Inc. seller in Q4 2016 was Fidelity Investments, an estimated $31M sold.
Based on aggregated 13F filings for Q4 2016.